So-Young International operates China's leading online-to-offline platform for medical aesthetics, connecting consumers with cosmetic treatment providers while expanding its own branded clinic network. The company's recent results have been defined by a powerful pivot: its legacy information and reservation services are shrinking, while its branded aesthetic centers are scaling rapidly. In Q2 2026, aesthetic treatment revenue surged roughly 130% year over year and accounted for the majority of total revenue. The Q3 report will show whether this clinic-led growth engine can keep accelerating even as the company continues to invest in new centers and manage group-level losses. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Analysts expect So-Young to report a loss of about $0.05 per ADS on revenue near $75.9 million for the quarter ended September 30, 2026. That compares with a loss of $0.09 per ADS on revenue of roughly $54.3 million in the same period a year earlier, implying meaningful revenue growth alongside a narrower per-share loss. It is worth noting that Wall Street coverage of this small-cap name remains thin, so consensus figures should be treated with caution.
The company has already provided its own outlook. With its Q2 2026 results, management guided third-quarter aesthetic treatment services revenue to between RMB 352.0 million and RMB 362.0 million, representing 91.7% to 97.2% year-over-year growth. Beyond that top-line target, investors will watch same-store sales growth, the pace of new clinic openings, gross margin in the aesthetic treatment segment, and the number of centers turning profitable. So-Young has beaten consensus EPS estimates in five of its last six quarters, setting a high bar for execution. From what I see in the data, this track record suggests the company is delivering on its clinic expansion strategy.
Sentiment heading into the Q3 2026 report is cautiously constructive but centered on execution. So-Young has repeatedly topped consensus EPS estimates, and its shares responded positively following its record-setting Q2 release. Still, the stock remains volatile and well below prior highs, reflecting a thin analyst base and lingering questions about when the company will reach sustained group-level profitability. Key risk factors include rising costs tied to clinic expansion, elevated sales and marketing spending, and a continued decline in the legacy information and reservation services segment. Any sign that clinic growth is decelerating faster than guided, or that losses are widening rather than narrowing, could pressure the stock. I’m watching this closely as earnings approach.
The most important metric to watch is aesthetic treatment services revenue, which has now guided for roughly 92% to 97% year-over-year growth in Q3 2026. This figure matters because it reflects both new clinic openings and same-store momentum, the two levers that underpin So-Young's long-term 1,000-center ambition.
Investors should also track profitability at the center level. In Q2 2026, 47 of 65 clinics were profitable, and 51 generated positive operating cash flow. As the network scales, the ratio of profitable centers will signal whether the company's standardized operating model is genuinely improving economics or simply growing for growth's sake.
Finally, watch the pace of loss reduction. Q2 2026 net loss narrowed 37% year over year to RMB 22.7 million, but the company is still not profitable at the group level. Any update on margin trends, customer acquisition efficiency, or the scaling back of loss-making businesses will help investors judge how quickly the company can close that gap. Upcoming catalysts include further guidance on clinic openings and supply-chain partnerships. One thing that stands out is how quickly the clinic network can turn more locations profitable.
In preparing this review, I turned to Tickeron’s AI Screener to filter comparable names in the sector and cross-check technical signals. It helped surface a few peers showing similar expansion patterns, which added useful context without replacing the core fundamentals. The tool’s customizable filters made it straightforward to scan for volatility and performance metrics that align with So-Young’s profile. Overall, it served as a practical supplement to traditional research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for SY crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 16, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SY as a result. In 79 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.
SY moved below its 50-day moving average on October 14, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for SY moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for SY entered a downward trend on November 18, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SY's RSI Indicator exited the oversold zone, 37 of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for SY just turned positive on November 06, 2026. Looking at past instances where SY's MACD turned positive, the stock continued to rise in 31 of 38 cases over the following month. The odds of a continued upward trend are 82%.
Following a +6.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where SY advanced for three days, in 221 of 267 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
SY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.141) is normal, around the industry mean (4.523). P/E Ratio (-0.846) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.430) is also within normal values, averaging (1.536). SY has a moderately high Dividend Yield (0.052) as compared to the industry average of (0.011). P/S Ratio (1.067) is also within normal values, averaging (6.105).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. SY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of online information and reservation services related to medical aesthetics
Industry ServicestotheHealthIndustry